Keratins 8 and 18 (K8 and K18) are heteropolymeric intermediate filament phosphoglycoproteins of simple-type epithelia. Mutations in K8 and K18 predispose the affected individual to liver disease as they protect hepatocytes from apoptosis. K18 undergoes dynamic O-linked N-acetylglucosamine glycosylation at Ser 30, 31 and 49. We investigated the function of K18 glycosylation by generating mice that overexpress human K18 S30/31/49A substitution mutants that cannot be glycosylated (K18-Gly -), and compared the susceptibility of these mice to injury with wild-type and other keratin-mutant mice. K18-Gly -mice are more susceptible to liver and pancreatic injury and apoptosis induced by streptozotocin or to liver injury by combined N-acetyl-d-glucosaminidase inhibition and Fas administration. The enhanced apoptosis in the livers of mice that express K18-Gly -involves the inactivation of Akt1 and protein kinase Cθ as a result of their site-specific hypophosphorylation. Akt1 binds to K8, which probably contributes to the reciprocal hyperglycosylation and hypophosphorylation of Akt1 that occurs on K18 hypoglycosylation, and leads to decreased Akt1 kinase activity. Therefore, K18 glycosylation provides a unique protective role in epithelial injury by promoting the phosphorylation and activation of cell-survival kinases.
1
. Mutations in intermediate filaments cause or predispose affected individuals to a wide range of human diseases that generally reflect the tissue-specific expression of the mutant intermediate filament gene 2, 3 . In epithelial cells, K8 and K18 are obligate noncovalent heterodimers and are the major intermediate filament proteins in simple-type epithelia 4, 5 . As such K8 and K18 are found in a range of organs, including the digestive tract, lung and kidney. Individual mutations in K8 and K18 are typically dominant, and predispose their carriers to acute or chronic liver disease progression [6] [7] [8] [9] . Keratins (including K8/K18) have several mechanical and non-mechanical functions, including cytoprotection from cell stress and apoptosis 4, 8 , regulation of epithelial polarity, protein targeting to subcellular compartments 4, 10, 11 and regulation of translation 12 . Keratin functions are facilitated by the dynamic interaction with associated proteins and by post-translational modifications such as serine phosphorylation, which is well-characterised in K8/K18 13 . The in vivo significance of phosphorylation at K8 Ser 74 and K18 Ser 34/Ser 53 was demonstrated in studies of transgenic keratin-mutant mice that were susceptible to liver injury (in strains of mice overexpressing K8 S74A or K18 S53A ) or that had altered mitotic progression and filament organization (in mice expressing the K18 S34A mutant) 13, 14 . K8 and K18 also undergo dynamic single O-linked N-acetylglucosamine (O-GlcNAc) Ser/Thr glycosylation 15 . Three O-GlcNAc glycosylation sites at Ser 30, 31 and 49, which do not seem to undergo phosphorylation, have been identified in human K18, although their function is not known 16 . K8 and K18 glycosylation and phosphorylation are concurrent 17 and probably occur at distinct residues (in contrast to some other proteins that undergo O-GlcNAc glycosylation 18, 19 ). For example, K8 and K18 are hyperglycosylated and hyperphosphorylated during mitotic arrest or viral infection in cultured cells 17, 20 , whereas inhibition of protein phosphorylation also prevents stimulus-induced K8/K18 hyperglycosylation 21 . O-GlcNAc residues are added and removed from serine/threonine by O-GlcNAc transferase and N-acetyl-D-glucosaminidase (O-GlcNAcase), respectively 18, 22 . O-GlcNAcylation modifies numerous nuclear/cytoplasmic proteins, and regulates several functions including protein turnover, transcription and stress responses 18, [22] [23] [24] [25] [26] [27] . O-GlcNAcylation and phosphorylation frequently occur at adjacent or identical serine and threonine residues, and each modification can interfere with the other 18, 22, 23, 28 . Exposure of animal models to streptozotocin (STZ), an O-GlcNAcase inhibitor that also has other non-O-GlcNAcase effects 29 , results in accumulation of O-GlcNAc-modified proteins, diabetes and neurodegeneration 18 . Similarly, exposure of adipocytes to PUGNAc (O-(2-acetamido-2-deoxy-d-glucopyranosylidene)amino-N-phenylcarbamate), another O-GlcNAcase inhibitor, leads to insulin resistance 30 but no reported studies tested the function of site-specific glycosylation in animal models.
To investigate the function of K18 glycosylation, mice that overexpress human K18 S30/31/49A substitution mutants (K18-Gly generated. We then compared their susceptibility to STZ-or combined PUGNAc/Fas-mediated injury with non-transgenic mice, mice that overexpress human wild-type K18 (ref. 31 ) and mice expressing K18 S53A (a non-phosphorylatable substitution-mutant; ref. 13 . Each lane represents separate livers that were used to generate a highly enriched keratin fraction by high-salt-extraction or that were solubilized in SDScontaining sample buffer to prepare total lysates 51 . The samples were separated by SDS-PAGE and stained with Coomassie blue, or were blotted with antibodies specific to human K18 (hK18), mouse K18 (mK18), mouse K8 (mK8) or the human K18 wild-type amino-acid squence (residues 27-39) RPVSSAASVYAGA (hK18 WT) 51 . This antibody does not recognize the K18-Gly -mutant because of mutation of serines 30 and 31 to alanine. (c) In vitro galactosylation of K8 and K18. K8 and K18 immunoprecipitates, from livers of mice with the same backgrounds as indicated in b, were obtained by using the human K18-specific antibody L2A1 (ref. 51) and then subjected to in vitro galactosylation using UDP-4,5-3 H-galactose and galactosyltransferase to radiolabel K8 and K18 Ser/ Thr-linked O-GlcNAc residues. Note that mutation of the three K18 S30/31/49 glycosylation sites abolished K18 glycosylation in the livers of mice expressing K18 Gly
H-galactosylation of detergent-free cytosolic extracts isolated from the livers of transgenic wild-type K18-and K18-Gly --expressing mice 2 days after STZ administration. Equal amounts of protein were separated by SDS-PAGE, followed by Coomassie staining or fluorography to assess the extent of protein O-GlcNAc modification. (e, f) Mice with the indicated genotypes (total number of mice assayed from each genotype are shown in f; all are in an FVB/N background) were injected with STZ then monitored daily for survival. Most deaths occurred within 10 days and no deaths were observed beyond 24 days. Mortality was significantly increased in the K18 Gly --expressing mice, compared with other mice strains (approximately 70% K18 Gly --expressing mice versus approximately 20-40% in the other listed control strains, P = 0.0002). Asterisk indicates P value when comparing FVB/N and mice expressing wild-type human K18 with mice expressing mutated K18.
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are significantly more susceptible to STZ-or combined PUGNAc/Fasinduced liver and pancreatic injury, including prominent hepatocyte apoptosis. K18-null mice phenocopy mice that express K18-Gly -. The observed susceptibility to cell death is specific to O-GlcNAcase inhibition since Fas-ligand alone induces apoptosis similarly in K18-Gly --expressing and control mice. The enhanced apoptosis in mice that express K18-Gly -involves Akt1 and protein kinase Cθ (PKCθ) inactivation through site-specific kinase hypophosphorylation in vivo and ex vivo. Akt1 binds to K8 and its inactivation by K18 hypoglycosylation is coupled by reciprocal Akt1 hyperglycosylation and hypophosphorylation. Our findings demonstrate a functional role for intermediate filament glycosylation by promoting cell survival through Akt1 activation.
RESULTS

Expression of K18-Gly
-mutant protein in transgenic mice A genomic human-K18 construct, identical to that used to generate several other transgenic mice that overexpress K18 (ref. 8) , was used to introduce point mutations into K18 to block glycosylation of the three main, previously identified 16 , glycosylation sites (Fig. 1a) . The expression of human K18 Gly - (Fig. 1b) and ablation of K18 glycosylation were confirmed by in vitro galactosylation (Fig. 1c) , which labels endogenous terminal GlcNAc modifications, and by an epitope-specific antibody that recognizes wild-type K18 but not the K18-Gly -mutant (Fig. 1b ). An advantage of the keratin-overexpression models is that endogenous mouse K18 expression decreases in parallel to human K18 overexpression (Fig.  1b) . Given that K18 phosphorylation and glycosylation involve proximal residues (Fig. 1a) , we tested whether K18-Gly -affects K18 Ser 34 or Ser 53 phosphorylation in transfected cells. K18 Ser 34/Ser 53 phosphorylation was assessed using an antibody specific to K18 phosphorylated at Ser 53 or by binding of 14-3-3 proteins to K18, which is regulated by K18 Ser 34 phosphorylation 13 . The K18 glyco-mutations have no effect on K18 Ser 34/ Ser 53 phosphorylation ( Supplementary Information, Fig. S1 ), which indicates that any observed phenotype of K18-Gly --expressing mice is not due to alteration in phosphorylation of K18 Ser 34 or Ser 53.
-predisposes transgenic mice to STZinduced injury K18-Gly --expressing mice are viable, breed normally, and have normal lifespan and histological phenotypes under basal conditions. Given that K18 glycosylation increases during stress-inducing cell-culture conditions, such as mitotic arrest or rotavirus infection 17, 20 , we first tested the susceptibility of K18-Gly -mice to STZ treatment. The overall O-GlcNAc content of proteins increased similarly (approximately 40%) in cytosolic liver homogenates of mice expressing wild-type K18 or K18-Gly -after STZ treatment (Fig. 1d) . However, K18-Gly -mice are markedly more susceptible to STZ-induced lethality (Fig. 1e, f) , which is accompanied by significantly higher serum alanine aminotransferase and lower serum insulin, compared with controls (Supplementary Information, Table S1 ). In contrast, no statistically significant differences were noted after STZ administration when comparing control mice with mice expressing K18 S53A or K18 R90C (Fig. 1f) . Notably, K18 S53A or K18 R90C mice have increased susceptibility to hepatotoxins, including microcystin-LR (MLR, a phosphatase inhibitor) or Fas-ligand, respectively 8, 32 . However, K18-Gly -mice had similar injury when compared with non-transgenic mice and mice expressing wild-type K18 after injection with Fas alone ( Supplementary  Information, Fig. S2 ) or treatment with MLR (not shown). These results indicate that K18-Gly -mice are selectively and highly susceptible to specific types of apoptosis-associated injury (for example, STZ but not Fas).
The increased lethality in K18-Gly -mice was probably caused by multiorgan failure since several abdominal organs (liver, pancreas and kidney; Fig.  2a ) were markedly paler in mice expressing K18-Gly -versus those expressing wild-type K18. These findings were confirmed by histological analysis that showed extensive liver haemorrhage and cell drop-off, pancreatic oedema and islet-cell necrosis in K18-Gly -mice ( Fig. 2b ; Supplementary  Information, Fig. S3 ). Also, there was significant hepatic steatosis and glycogen depletion in K18-Gly --expressing mice, as confirmed by oil red-O and periodic acid-Schiff staining, respectively (Fig. 2c) . Pancreatic endocrine damage was corroborated by the markedly decreased insulin staining (Fig. 3a) and lower serum insulin (Supplementary Information, Table S1 ) in the pancreata of K18-Gly --expressing mice. The predisposition to STZmediated pancreatic damage is not related to differences in glucose or insulin tolerance ( Supplementary Fig. S4 ). Collectively, these findings indicate that the marked STZ-mediated injury in mice expressing K18-Gly -is not related to selective glucose homeostasis changes but to generalized epithelial tissue injury in several K18-expressing organs.
Next, we examined the cause of cell death in K18-Gly --expressing mice. No effect on liver and pancreas keratin filament organization under basal conditions was noted ( Supplementary Information, Fig. S5a ), but immunostaining of liver and pancreas after STZ treatment showed a marked increase in K18 apoptotic fragment formation and more prominent mouse K8 Ser 80 phosphorylation (a stress sensor 13 ) that is identical to human Ser 74, when compared with tissues from mice expressing wildtype K18 ( Supplementary Information, Fig. S5b, c) . Increased apoptosis in the tissues of K18-Gly --expressing mice (liver more than pancreas) was supported by blotting with antibodies to cleaved caspase-3 and the K18 apoptotic fragment (Fig. 3b, c) . Hence, the liver injury involves extensive apoptosis, whereas the pancreatic injury includes limited apoptosis, which is consistent with experimental pancreatitis models where apoptosis (rather than necrosis) is typically inversely proportional to the severity of pancreatitis 33 .
-predisposes transgenic mice to PUGNAc/Fas-induced injury The protective role of K18 glycosylation is further confirmed by using a more selective O-GlcNAcase inhibitor, PUGNAc 29 , combined with Fas antibody. Given that the effect of PUGNAc is not well-studied in mice, we first tested various doses of PUGNAc in non-transgenic mice. Although all mice appeared normal and had no liver damage, PUGNAc caused liver accumulation of O-GlcNAc-proteins (Fig. 4a ). Fas-antibody administration 2 days after PUGNAc treatment showed that the K18-Gly -mice are significantly more susceptible to lethality, compared with controls ( Fig. 4b, c) . PUGNAc/Fas treatment phenocopies the severe liver haemorrhage, apoptosis, hepatic steatosis and glycogen depletion ( 
K18-Gly
-alters protein kinase phosphorylation in mouse hepatocyte primary cultures treated with STZ The phosphoinositide 3-kinase (PI3K) pathway is central to hepatic glucose, lipid and insulin metabolism 34 . Phosphorylation of the PI3K effectors, Akt1 and glycogen synthase kinase (GSK), is inhibited in adipocytes using a GlcNAcase inhibitor 30 . Hence, we tested if K18-Gly -expression affected Akt1 and GSK phosphorylation after STZ treatment in primary hepatocyte cultures, and also assessed hepatocyte susceptibility to apoptosis after STZ exposure in vivo. Phosphorylation of Akt1 Thr 308 and its substrate GSK3α Ser 21 were markedly inhibited in K18-Gly -hepatocytes, whereas cleaved caspase-3 was more prominent in the hepatocytes of K18-Gly -mice (Fig. 5a) , which parallels the profound apoptosis that is seen in intact livers (Fig. 3b) . The effects on phosphorylation of Akt1 Thr 308 and GSK3α Ser 21 were selective as phosphorylation of GSK3β Ser 9, PTEN Ser 380 and MAPK p38 Thr 180/Tyr 182 were similar in all three mouse genotypes (Fig. 5a ). Wild-type human K18 from transgenic mice and Akt1 Thr 308 and GSK3α Ser 21 from the hepatocytes of non-transgenic mice were highly phosphorylated, even under basal conditions ( Fig. 5a ; lanes 1 and 6), and their phosphorylations were minimally affected after STZ treatment (Fig. 5a ) which is probably because of the stress induced during hepatocyte isolation and culture.
Expression of K18-Gly -alters protein kinase phosphorylation upon exposure to STZ in vivo We then examined Akt1 Thr 308 and GSK3α Ser 21 in-situ phosphorylation in mice expressing wild-type K18 and K18-Gly -after STZ administration. In contrast to primary hepatocyte cultures (Fig. 5a) , induction of GSK3α Ser 21 phosphorylation was similar in the livers of mice expressing wild-type K18 and K18-Gly -after STZ-injection (Fig. 5b) . However, Akt1 Thr 308 phosphorylation increased 12 h after STZ injection in the livers of mice expressing wild-type K18 but did not increase after up to 70 h in the livers of mice expressing K18-Gly - (Fig. 5b) . in vivo results show enhanced susceptibility of K18-Gly --expressing mice hepatocytes to apoptosis in association with site-specific blunting of Akt1 Thr 308, but not Akt1 Ser 473 phosphorylation (Fig. 5a, b) . Consistent with this finding, Akt1 activation leads to cell survival, proliferation and growth 35, 36 , whereas disruption of mouse Akt1 causes growth retardation and increased apoptosis 37 . Notably, Akt1 Thr 308 (the activation loop phosphorylation site) mutation abolishes its kinase activity whereas Ser 473 mutation results in partial inactivation 38 . The AGC family of kinases (Akt/PKA/PKC) share a conserved (T-F-C-G-T) activation-loop phosphorylation motif (Thr 308 in Akt1) that is phosphorylated by PDK1 (ref. 39 ; Fig. 5c ). We tested whether phosphorylation of the comparable threonine in PKC isoforms is inhibited in livers of mice expressing K18-Gly -treated with STZ. Similarly to Akt, PKCθ Thr 538 but not Ser 676 hyperphosphorylation is markedly reduced in the livers of K18-Gly --expressing mice after STZ exposure (Fig. 5d) . Phosphorylation of the PDK1 consensus threonines of other tested PKC isoforms (α/β/δ/ξ/λ) showed no, or limited, changes in phosphorylation differences when comparing STZ-treated livers of K18 -Gly --expressing mice with mice expressing wild-type K18 (Fig. 5d) . Notably, a PKCθ T538A mutant disrupts PKCθ activity, whereas a S676A mutation results in limited inactivation 40 . In T cells, PKCθ is critical for cell activation and promotes survival by antagonizing apoptotic signals 41 . Therefore, blocking K18 glycosylation leads to site-specific inhibition of Akt1 Thr 308-and PKCθ Thr 538-phosphorylation, providing an additional potential explanation for the observed accelerated STZ-induced apoptosis in the livers of K18-Gly --expressing mice. The selective site-specific differences in PDK1 substrate phosphorylation of Akt1/PKCθ are not related to differences in PDK1 activation as its activity, based on PDK1 Ser 241 phosphorylation, is similar in the livers of wild-type K18-and K18-Gly --expressing mice (Fig. 5b) . The effects that are seen in Akt1 Thr 308 /PKCθ Thr 538 phosphorylations are selective to the liver and are not present in the pancreas (Fig. 5e) , which suggests that the mechanism of liver injury is distinct from the pancreas. This is supported by the limited apoptosis in the pancreas versus liver of K18-Gly --expressing mice after STZ exposure (Fig. 3b, c and Supplementary  Information, Fig. S5b) of K18-Gly --expressing mice, with a minimal effect on PKCθ Thr 538 phosphorylation (Fig. 6a, b) . After PUGNAc/Fas treatment, Akt1 Thr 308 phosphorylation and Hsp70 protein levels were markedly decreased in the livers of K18-Gly --expressing mice, which was correlated with an increase in the levels of cleaved caspase-3 (Fig. 6c) . Akt1 is a known modulator of HSF1, which in turn, leads to transcriptional upregulation of Hsp70 (ref. 42) . Hence, inhibition of K18 glycosylation inactivates Akt1 and blocks its downstream regulation.
Effect of PUGNAc on Akt1 glycosylation
Given the potential reciprocity between serine and threonine phosphorylation and glycosylation, we tested if mutation of Akt1 Thr 308 also affects
O-GlcNAcylation. PUGNAc causes accumulation of O-GlcNAc proteins in BHK cells transfected with wild-type Akt1 or an Akt1
T308A mutant (Fig. 6d) . PUGNAc treatment results in Akt1 Thr 308 hypophosphorylation (Fig. 6d) . To test the effect of Akt1 Thr 308 phosphorylation on Akt1 glycosylation, the O-GlcNAc proteins were immunoprecipitated from transfected cells using two independent anti-O-GlcNAc antibodies then blotted with anti-Akt1 antibody. Compared with wild-type Akt1, Akt1
T308A was much less efficiently immunoprecipitated using both O-GlcNAc antibodies under conditions that immunoprecipitated similar levels of endogenous O-GlcNAc-vimentin (Fig.  6e) . These findings indicate that the O-GlcNAc modification occurs at or near Akt1 Thr 308, although an effect of the Thr 308 mutation on other Akt1 serine and threonine modifications is also possible. Expression of K18-Gly -inhibits Akt1 Thr 308 phosphorylation and decreases Hsp70, which is acccompanied by enhanced apoptosis in response to PUGNAc/Fas treatment. (a, b) FVB/N mice (a), or mice expressing wild-type K18 or K18-Gly -(b) were given PUGNAc (7 mg per kg body weight) or vehicle. Livers were harvested at the indicated times after PUGNAc injection and total liver lysates were blotted with antibodies specific to the indicated antigens. (c) Mice expressing wild-type K18 or K18-Gly -were pre-treated with PUGNAc for 48 h then injected with Fas antibody. Livers were harvested at 2, 5, 7 and 9 h after Fas injection and total liver lysates were immunoblotted with antibodies specific to the indicated antigens. Akt1 Thr 308 phosphorylation increased 2 h after PUGNAc and Fas treatment in the livers of mice expressing wild-type K18 (4.9-fold; compare lanes 1 and 2) but the increase in the livers of mice expressing K18 Gly -was limited. (d) BHK cells were transfected with vector alone, wild-type Akt1 or an Akt1 T308A mutant. After 2 days, the transfected cells were treated with 100 μM PUGNAc for 18 h. Total cell lysates were prepared and blotted with antibodies specific to the indicated antigens. Note that O-GlcNAc proteins accumulated after PUGNAc treatment (lanes 4 and 5). The expression of wild-type Akt1 and the Akt1 T308A mutant were confirmed using antibodies specific to Akt1 or phosphorylated Akt1. (e) Transfected BHK cells (with wild-type Akt1 or the Akt1 T308A mutant) were treated with 100 μM PUGNAc for 18 h. O-GlcNAc proteins were immunoprecipitated with two different O-GlcNAc antibodies, Ab110.6 or AbRL2. The immunoprecipitates were analysed by blotting with antibodies specific to Akt1 or vimentin (as a loading control). Note that similar patterns were obtained by using two different O-GlcNAc antibodies. IgG, immunoglobulin G. Uncropped images of blots are shown in Supplementary Information, Fig. S7 .
Akt1 associates with K8 but not with K18
Akt1 binds to the amino-terminal region of K10 (which is expressed in keratinocytes) and this physical interaction causes sequestration of the kinase within the cytoskeleton 43 . The relationship between K18 glycosylation and Akt1 glycosylation/phosphorylation was investigated by finding out whether Akt1 binds to K8/K18 and, if so, whether this binding depends on K18 glycosylation or Akt1 phosphorylation. As shown in Figure 7 , K8/K18 co-immunoprecipitate with Akt1, using anti-K8/K18 or anti-Akt1 antibodies, when isolated from transfected cells (panel a) or from the livers of wild-type K18-or K18-Gly --expressing mice (panel b). However, the K8/K18-Akt1 interaction is independent of keratin glycosylation, when tested using K18-Gly -transfectants or transgenic mice (Fig. 7a, b) , and is also independent of Akt1 Thr 308 phosphorylation (Fig. 7a) . Transfection of BHK cells with K8, K18, K8 and K18, or individual keratin deletion mutants showed that both K8 and K18 co-immunoprecipitated with Akt1 (Fig. 7c, lane 2) , owing to the known obligate . Total cell lysates were also prepared from the transfected cells and blotted with antibody 8592 which recognizes K8 and K18. Asterisks represent major bands of the indicated protein in the blot, whereas other weak bands in the same positions represent degraded K8 or background bands also found in Akt-transfectants (lane 1). Akt1 immunoprecipitates were also prepared and blotted with the indicated antibodies specific to the indicated antigens. (d) BHK cells were transfected as in c. Akt1 immunoprecipitates were prepared and blotted with antibodies specific to K8/K18 or Akt. Expression of wild-type K8 and K8 (1-253) were similar as can be seen in the blot of the total lysates in c (lanes 3 and 4) . The displayed K8/K18 blot shows the details of the antibody reactive species in the range of 28-53 K. Note that intact wild-type K8 (483 amino acids) co-precipitated with Akt1 (lane 2), but the K8 N-terminal fragment (1-253) did not (lane 3). The band marked with the arrow represents secondary antibody crossreactivity.
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heterodimeric nature of K8/K18, but single keratin transfections showed Akt1 association with K8 (Fig. 7c, lane 3) but not K18 (Fig. 7c , lane 5 and see Fig. 7d for an independent experiment). The Akt-K8 binding does not involve the N-terminal domains of K8 or K18 (Fig. 7d) , thereby suggesting that association of Akt1 with K8 probably occurs through the K8 carboxy-terminal domain within amino acids 254-483.
DISCUSSION
Our findings demonstrate that site-specific ablation of K18 O-GlcNAc glycosylation in mice leads to injury susceptibility that is related to STZ or a combined effect of treatment with PUGNAc and Fas. Blocking K18 glycosylation does not predispose mice to apoptosis or tissue injury per se (Fig. 2, Supplementary Information, Fig. S2 ) but requires another stress that inhibits O-GlcNAcase and thereby raises the intracellular levels of protein O-GlcNAcylation (Figs 1d and 6d) . Therefore, K18 glycosylation seems to function as a cytoprotective and anti-apoptosis buffer during conditions that promote increased protein O-GlcNAcylation. The cytoprotective role of K18 glycosylation seems to be different in the liver versus the pancreas since the site-specific hypophosphorylation of Akt1 and PKC that was observed in the liver was not observed in the pancreas (Fig. 5e ), thereby invoking organ-specific effects of K18 glycosylation. The stoichiometry of K18 glycosylation is estimated to be approximately two molecules of O-GlcNAc per keratin molecule 15 , which provides a potentially robust buffering capacity owing to K18 abundance as a major cytoskeletal protein of simple epithelia (for example, K8 and K18 constitute approximately 0.3% of total mouse liver protein 32 ). The buffering capacity of K18 glycosylation is related to specific proteins that include signalling kinases (for example, Akt1 as demonstrated here) and is not a global effect since not all proteins became hyperglycosylated in K18-glycosylation deficient liver (Fig. 1d) .
The protective effect of K18 glycosylation in mice is highly specific to this post-translational modification, as mice that overexpress the K18 S53A (ref. 44) or the K18 R90C mutants (which disrupt the keratin filament network of hepatocytes and renders them susceptible to Fas-mediated apoptosis 45 ) react similarly to wild-type mice when exposed to STZ. Notably, K18 R90C in vivo expression results in hyperglycosylation (and hyperphosphorylation) of K8/K18 (ref. 46) , which given the findings here, raises the possibility that K18 hyperglycosylation may have a protective function that can partially compensate for the effect of the R90C mutation. In addition, mice that express wild-type K18 or K18-Gly -display similar susceptibility to injury mediated by treatment with Fas. This is in contrast with the disruptive structural effect of K18 R90C on keratin cytoplasmic filament organization and the consequent predisposition to Fas-mediated apoptosis, which suggests that the K18-Gly --expressing mice cytoprotective phenotype is unlikely to be due to a structural effect of the three K18 serine to alanine mutations that were introduced to inhibit K18 glycosylation. Further support for the specificity of our findings is based on the observation that K18-null mice 47 are also predisposed to STZ-induced liver and pancreatic injury ( Supplementary Information, Fig. S6) .
O-GlcNAcase inhibition unmasks a new K18 glycosylation function that protects K18-expressing epithelial tissues from injury, and links glycosylation of the keratin cytoskeleton to activation of cell survival kinases. Our findings support a model (Fig. 8) whereby K18 glycosylation induces activation of Akt1 by phosphorylation of Thr 308, which inhibits cell death. Phosphorylated Akt1 Thr 308 is probably hypoglycosylated as O-GlcNAcase inhibition by PUGNAc or STZ leads to Akt1 hypophosphorylation (Figs 5b and 6d) . Also, the Akt1 T308A mutation decreases Akt1 glycosylation as measured using two independent anti-O-GlcNAc antibodies (Fig. 6e) . Hence, these results implicate reciprocal phosphorylation and glycosylation at or near the Akt1 Thr 308 residue, where each type of modification interferes with the other. The importance of O-GlcNAcase in regulating Akt1 phosphorylation and activity is also supported by the previously reported increase in Akt1 phosphorylation at Thr 308 on overexpression of O-GlcNAcase in mouse liver 48 . Therefore, K18 glycosylation provides its protective effect probably by promoting Akt1 phosphorylation at the critical Thr 308 residue that regulates its kinase activity and through PKCθ phosphorylation at Thr 538, although additional regulatory phospho/glyco-proteins may be involved. Such crosstalk between O-GlcNAcylation and phosphorylation is an emerging model in the regulation of several signalling cascades related to coping with stress, including those involving NFκB and other transcription factors 19 . The relationship of reciprocal Akt1 glycosylation and phosphorylation in response to glycosylation of K18 does not seem to be mediated by upstream kinase regulation of Akt1, such as PDK1 activation ( Figs  5 and 6 ). The binding of K8 to Akt1, albeit in a K18 glycosylation and Akt1 Thr 308-independent manner (Fig. 7) , suggests that the K8-K18 obligate heterodimeric complex that provides a scaffold for Akt1 is akin to the association of K10 with Akt 43 . It remains to be determined whether K18 glycosylation facilitates recruitment of Akt kinase(s) or O-GlcNAcase given the general property of O-GlcNAcylated proteins to form multimeric complexes 19 . Such potential recruitment could promote Akt1 hyperphosphorylation and hypoglycosylation, which in the absence of K18 glycosylation (for example, in mice expressing K18-Gly -) could lead to the opposite effect of Akt1 hypophosphorylation and hyperglycosylation. Similar effects can occur if glycosylated K18 is to recruit Akt phosphatase(s), and parallel paradigms might account for the observed PKCθ Thr 538 hypophosphorylation as a consequence of K18 hypoglycosylation. However, PKCθ Thr 538 phosphorylation does not appear to be significantly affected in the presence of PUGNAc when compared with Akt1 Thr 308 phosphorylation, which raises the possibility that more than one mechanism may be involved in transmitting the K18 glycosylation signal to a kinase inactivation effect.
Akt
Akt-T308-P Cell Death Figure 8 Model of K8 association with Akt1 and the effect of K18 glycosylation on reciprocal Akt1 phosphorylation and glycosylation. The schematic summarizes the results of the genetic animal models whereby ablation of K18 glycosylation or absence of the entire K18 protein in K18-null mice leads to Akt1 hypophosphorylation and inactivation, which in turn promotes cell death. Inhibition of Akt1 Thr 308 phosphorylation (by the Akt1 T308A mutation) inhibits Akt1 glycosylation (which may occur at Thr 308 or an adjacent site), whereas hyperglycosylation of Akt1 (presumably at or near Thr 308) leads to Akt1 hypophosphorylation at its regulatory Thr 308 residue.
In summary, our findings provide a link between keratin glycosylation and critical reciprocal kinase regulation by phosphorylation and glycosylation, which leads to anti-apoptotic and cytoprotective effects, as shown here for Akt1 in the liver. These findings may extend to other intermediate filaments that are known to have the O-GlcNAc modification such as neurofilaments 49 and vimentin 50 .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/ . Dilutions of the above antibodies, except-anti-keratin antibodies, are 1:1,000 for immunoblotting and 1:100 for immunostaining. For antibodies specific to keratins and phospho-keratins dilutions of 1:1,000 were used for immunoblotting and 1:50 for immunofluorescence microscopy.
M E T H O D S
Generation of transgenic lines. The 10 kb human K18 genomic DNA was mutated at three glycosylation sites (S30/31/49A) using a Transformer Mutagenesis kit (Clontech). This genomic construct contains all the regulatory elements needed to retain normal tissue-specific expression 31 . The mutated genomic DNA (Gly -) was used for injection into pronuclei of fertilized FVB/N mouse eggs. Progeny mice were screened by PCR amplification of mouse tail genomic DNA for the presence of human K18. Two independent heterozygous mouse lines were established and both lines gave similar results (data not shown). The two K18-Gly --expressing mutant lines had comparable expression of human K18 protein to the mouse line expressing wild-type human K18. The human and mouse K18 amino acid sequences show 86% sequence identity and 92% sequence similarity (accession numbers: NP_000215.1 , human K18 and NP_034794.2, mouse K18).
The other experimental lines included mice expressing human K18 S53A (which ablates a major K18 phosphorylation site) 13 , human K18
R90C that causes keratin filament disruption and predisposes to apoptosis 32 , and K18-null mice (originally provided by T. Magin, University of Leipzig and now available through The Jackson Laboratory). All mouse transgenic lines were in an FVB/N background. The K18-null mouse (originally in a mixed strain background 47 ) was backcrossed to an FVB/N background for six generations.
Drug administration. Mice were fasted overnight before each drug administration. Mice were injected intraperitoneally with STZ (200 mg per kg body weight) or vehicle (50 mM sodium citrate at pH 4.5). Alternatively, mice were injected intraperitoneally with PUGNAc (7 mg per kg body weight) or vehicle (PBS), and after 48 h the mice were treated with Fas antibody (0.15 mg per kg mouse body weight). Mice were then euthanized by CO 2 inhalation. Blood was collected by intracardiac puncture, and tissues were: fixed in 10% formalin for hematoxylin/ eosin staining, fixed in acetone for immunofluorescence staining, or frozen in liquid nitrogen for subsequent biochemical analysis 51 . Blood glucose was measured from tail blood using an automated glucose monitor (One Touch Ultra, Lifescan). Insulin levels were determined by ELISA (enzyme-linked immunosorbent assay; Insulin ELISA kit, Linco Research).
In vitro galactosylation, immune staining and blot analysis. In vitro galactosylation was performed using keratin immunoprecipitates (obtained by using the human K18-specific antibody L2A1; ref. Figure S1 K18 Gly -(S30/31/49→A) does not affect K18 S34/S53 phosphorylation. BHK cells were co-transfected with K8 WT and K18 WT, or with K8 WT and K18 Gly -. Transfected cells were cultured in the absence or presence of okadaic acid (OA, 1 μg/ml, 2 hr), a phosphatase inhibitor that leads to accumulation of phosphorylated proteins in cells. K8/K18 were immunoprecipitated and blotted with antibodies to K18 pS53 or 14-3-3 proteins (14-3-3 proteins bind to K18 pS34). HK8 represents K8 pS74 species (a hyperphosphorylated form of K8). Arrowheads point to keratin fragments. Note that K18 hyperphosphorylation is independent of mutating the K18 glycosylation sites.
Fig. S1
Figure S2 K18 Gly -mice are not predisposed to Fas-induced injury. a, Ageand sex-matched mice from the three indicated genotypes (non-transgenic FVB/n, K18 WT and K18 Gly -mice) were given Fas ligand (antibody Jo2; Pharmingen) by intraperitoneal administration (0.15 mg/kg mouse body weight). Mice were then assessed hourly for the first 12 hr and then every 10 hr for 3 days. Most deaths were observed within the first 12 hr and no deaths were noted after 50 hr. b, Summary of the mouse mortality that is graphed in panel (a). Most apoptotic cells (red) colocalized with S80-phosphorylated cells (green) thereby providing the merged yellow color, but not all S80+ cells were apoptotic. This suggests that mK8 S80 phosphorylation occurs first and is then followed in some cells by apoptosis. The colocalization of cleaved C3 and mK8 pS80 in WT liver after STZ treatment was not detected due to very weak staining of cleaved C3 (not shown). Bar: 200 μm. Figure S6 K18-null mice have increased susceptibility to STZ-mediated tissue injury. a, K18-null mice and non-transgenic FVB/n mice were injected intraperitoneally with 200 mg/kg mouse body weight of STZ. After 2 days, livers and pancreata were isolated and stained with hematoxylineosin. Similar histological staining patterns were observed under basal conditions (not shown). However, after STZ treatment, the K18-null mice manifested more severe liver hemorrhage, pancreatic edema and islet cell necrosis as compared with the non-transgenic mice that had minimal liver hemorrhage and blood infiltration into the pancreatic islets. N, nontransgenic mice; H, hemorrhage; E, edema. Bar: 200 μm in 100x, 50 μm in 400x. b, Mice from the indicated genotypes were injected with STZ (200 mg/kg mouse body weight). After 2 days, total liver lysates were prepared from the STZ-treated or from control mice followed by blotting with antibodies to the indicated antigens. Each lane represents analysis of an independent mouse liver. The actin blot is included to demonstrate near-equal protein loading. Figure S7 . Full scan of key immunoblots 
